Familial Hypercholesterolemia: Clinical Trials

14 trials for Familial Hypercholesterolemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 1 enrolling by invitation. 14 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 314Completed 13, Enrolling by invitation 1

Follow Familial Hypercholesterolemia: new trials by email Literature Review of Familial Hypercholesterolemia trials Research Report on Familial Hypercholesterolemia

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe - Dyslipidemias, Hypercholesterolemia
Phase 3CompletedNewAmsterdam Pharma4072024-03-012025-10-08
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
Enlicitide Decanoate, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia
Phase 3CompletedMerck Sharp & Dohme LLC29122023-08-102026-09-24
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
Enlicitide Decanoate, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia
Phase 3CompletedMerck Sharp & Dohme LLC3032023-08-082026-02-24
Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
Obicetrapib, Placebo - Dyslipidemias, High Cholesterol
Phase 3CompletedNewAmsterdam Pharma3542022-07-252025-06-11
Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)
Motivational interview (MI) - Familial Hypercholesterolemia, Cholesterol, Elevated
Phase 3CompletedEssentia Health2572022-02-152026-09-04
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
Placebo, Obicetrapib - Dyslipidemias, High Cholesterol
Phase 3CompletedNewAmsterdam Pharma25302021-12-152025-09-19
Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction
lerodalcibep - Cardiovascular Disease With Mention of Arteriosclerosis, Elevated Cholesterol
Phase 3Enrolling by invitationLIB Therapeutics LLC20002020-12-032024-10-22
Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)
Evolocumab - Familial Hypercholesterolemia
Phase 3CompletedAmgen1632016-09-102024-05-29
A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)
Ezetimibe, Rosuvastatin - Hypercholesterolemia, Familial Hypercholesterolemia
Phase 3CompletedOrganon and Co1352016-05-182024-05-16
Effect of Omega-3 Fatty Acid on Endothelial Function
Omega-3, placebo - Familial Hypercholesterolemia
Phase 3CompletedNordlandssykehuset HF342013-03-012019-05-13
Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia
lomitapide - Familial Hypercholesterolemia
Phase 3CompletedAegerion Pharmaceuticals, Inc.192009-10-292018-06-13
Atorvastatin Three Year Pediatric Study
atorvastatin - Familial Hypercholesterolemia
Phase 3CompletedPfizer's Upjohn has merged with Mylan to form Viatris Inc.2722009-03-012021-02-21
PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin
Rosuvastatin, Placebo - Familial Hypercholesterolemia
Phase 3CompletedAstraZeneca1732006-07-012011-08-31
Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018)
Atorvastatin, Simvastatin, Ezetimibe - Familial Hypercholesterolemia
Phase 3CompletedOrganon and Co502000-05-032024-05-10

Narrower conditions

Hyperlipoproteinemia Type II (14)  ·  Hypercholesterolemia (10)  ·  Dyslipidemias (3)  ·  Atherosclerosis (2)  ·  Genetic Diseases, Inborn (2)  ·  Homozygous Familial Hypercholesterolemia (2)  ·  Hyperlipoproteinemias (1)  ·  Lipid Metabolism Disorders (1)  ·  Lipid Metabolism, Inborn Errors (1)  ·  Metabolic Diseases (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14)  ·  Hyperlipidemias (14)  ·  Metabolism, Inborn Errors (14)  ·  Nutritional and Metabolic Diseases (14)  ·  Hyperlipoproteinemias (13)  ·  Lipid Metabolism Disorders (13)  ·  Lipid Metabolism, Inborn Errors (13)  ·  Metabolic Diseases (13)  ·  Genetic Diseases, Inborn (12)  ·  Dyslipidemias (11)  ·  Arterial Occlusive Diseases (2)  ·  Arteriosclerosis (2)  ·  Cardiovascular Diseases (2)  ·  Vascular Diseases (2)

Interventions

Ezetimibe (3)  ·  Atorvastatin (2)  ·  MK-0616 (2)  ·  Rosuvastatin Calcium (2)  ·  BMS201038 (1)  ·  Cholesterol Ester Transfer Proteins (1)  ·  Combined Modality Therapy (1)  ·  Docosahexaenoic Acids (1)  ·  Esomeprazole (1)  ·  Motivational Interviewing (1)  ·  Olive Oil (1)  ·  Omacor (1)  ·  Simvastatin (1)  ·  evolocumab (1)

Sponsors

NewAmsterdam Pharma (3)  ·  Merck Sharp & Dohme LLC (2)  ·  Organon and Co (2)  ·  Aegerion Pharmaceuticals, Inc. (1)  ·  Amgen (1)  ·  AstraZeneca (1)  ·  Essentia Health (1)  ·  LIB Therapeutics LLC (1)  ·  Nordlandssykehuset HF (1)  ·  Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1)

Countries

United States (11)  ·  Norway (7)  ·  Canada (6)  ·  Spain (6)  ·  Netherlands (5)  ·  South Africa (5)  ·  Czechia (4)  ·  Italy (4)  ·  Poland (4)  ·  Turkey (Türkiye) (4)  ·  Colombia (3)  ·  Hungary (3)  ·  Israel (3)  ·  Australia (2)  ·  Belgium (2)

Top investigators

Marc Ditmarsch (2)  ·  David Kallend, MB BCh (1)  ·  Marc Ditmarsch, MD (1)  ·  Marina Cuchel, MD, PhD (1)  ·  Mark Sumeray, MD (1)

Results publications

PMID 12034651, PMID 20223367, PMID 27678432, PMID 36520008, PMID 36999528, PMID 38705341, PMID 39531353, PMID 40337982, PMID 40347969, PMID 41109840, PMID 41206969, PMID 41760952, PMID 41879224, PMID 42054033

NIH funding

2008 (1), 2015 (1)